Skip to main content
Medical information Clinical review pending

Genetic Testing

NOD2 Gene Sarcoidosis Early-Onset Genetic Test

This genetic test uses Next-Generation Sequencing (NGS) to identify mutations in the NOD2 gene associated with early-onset sarcoidosis. It can help in early diagnosis and management for individuals with a family history or symptoms.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
Results
Confirm turnaround time with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. Confirm with the laboratory for any specific instructions.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the NOD2 Gene Sarcoidosis Early-Onset Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Individuals with a family history of sarcoidosis.
  • ✓Patients presenting with symptoms suggestive of sarcoidosis (e.g., persistent cough, fatigue, skin lesions).
  • ✓Assessing genetic predisposition to early-onset sarcoidosis.
  • ✓Guiding clinical management and monitoring strategies.
02

In plain language

What this test helps you understand

Identifies genetic mutations in the NOD2 gene associated with early-onset sarcoidosis, aiding in risk assessment and diagnosis.
The NOD2 Gene Sarcoidosis Early-Onset NGS Genetic DNA Test is a diagnostic tool that uses Next-Generation Sequencing (NGS) technology to look for genetic changes in the NOD2 gene. These changes are linked to an increased risk of developing sarcoidosis, particularly when it starts at an early age. This test is valuable for individuals with a family history of sarcoidosis or those experiencing symptoms suggestive of the condition. Understanding your genetic predisposition can help healthcare providers make informed decisions about diagnosis, monitoring, and potential treatment strategies. This test analyzes a DNA sample to provide information about specific mutations in the NOD2 gene. Results are interpreted by healthcare professionals to assess individual risk and guide clinical management.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. Confirm with the laboratory for any specific instructions.
SampleBlood sample (EDTA tube) or extracted DNA. Confirm specific requirements with the laboratory before booking.
MethodologyNext-Generation Sequencing (NGS) of the NOD2 gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test identifies specific mutations in the NOD2 gene but does not guarantee the development of sarcoidosis. Sarcoidosis is a complex condition influenced by multiple genetic and environmental factors. A negative result does not completely rule out the possibility of developing sarcoidosis.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Sarcoidosis is a disease characterized by the formation of tiny collections of inflammatory cells (granulomas) in different parts of the body, most commonly the lungs and lymph nodes.
The NOD2 gene provides instructions for making a protein involved in the immune system's response to certain bacteria. Mutations in this gene have been linked to an increased risk of developing sarcoidosis.
This test may be considered for individuals with a family history of sarcoidosis, those experiencing symptoms suggestive of the disease, or those seeking to understand their genetic predisposition.
A healthcare provider will interpret the results in the context of your medical history and symptoms. Genetic counseling may be recommended to discuss the implications.
No, a positive result indicates an increased genetic risk but does not guarantee you will develop sarcoidosis. Other factors play a role.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp